Please assess the completion status of the following clinical trial:

Trial Title: Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed malignant melanoma or renal cell carcinoma~* At stage IV or relapse~* At least one prior chemotherapy including targeted agents~* At least one haploidential or partially matched-HLA donor~* ECOG performance status 0-1~* Age 18-75 years~* Measurable lesion~* Adequate bone marrow, liver, and renal functions~Exclusion Criteria:~* Chemotherapy within 4 weeks~* Stem cell transplantation~* Active CNS metastasis~* Hypersensitivity to IL-2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High-dose IL-2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).